{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:13:33Z","timestamp":1783440813685,"version":"3.54.6"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.transproceed.2021.04.020","type":"journal-article","created":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T16:43:41Z","timestamp":1623602621000},"page":"1519-1527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Heterogeneous Manifestations of Posttransplant Lymphoma in Renal Transplant Recipients: A Case Series"],"prefix":"10.1016","volume":"53","author":[{"given":"Rujuta","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Prashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2021.04.020_bib0001","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report: lymphomas after solid organ transplantation","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0002","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1046\/j.0007-1323.2001.01924.x","article-title":"Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients: lymphoproliferative disease in kidney transplant recipients","volume":"88","author":"Libertiny","year":"2001","journal-title":"Br J Surg"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-6143.2006.01650.x","article-title":"Epstein-Barr virus: evasive maneuvers in the development of PTLD","volume":"7","author":"Snow","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0004","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0006","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1111\/j.1432-2277.2000.tb02070.x","article-title":"Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection","volume":"13","author":"Buda","year":"2000","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0007","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1086\/514142","article-title":"Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease","volume":"176","author":"Ma\u00f1ez","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0008","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0009","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French Registry and Analysis of Subgroups of Lymphomas: PTLD French Registry","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0011","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archderm.140.9.1140","article-title":"Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients","volume":"140","author":"Beynet","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0012","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1432-2277.2006.00284.x","article-title":"Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab","volume":"19","author":"Svoboda","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0013","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00007890-200003150-00027","article-title":"Epstein-Barr virus-negative lymphproliferative disorders in long-term survivors after heart, kidney, and liver transplant","volume":"69","author":"Dotti","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0014","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00007890-200210270-00007","article-title":"Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome","volume":"74","author":"Dotti","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000144335.39913.5C","article-title":"Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?","volume":"79","author":"Ghobrial","year":"2005","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.transproceed.2021.04.020_bib0016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5144\/1658-3876.2011.73","article-title":"Very late onset lymphoproliferative disorders occurring over 10 years post-renal transplantation","volume":"4","author":"Khedmat","year":"2011","journal-title":"PTLD Int Survey Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/0886022X.2020.1759636","article-title":"Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population","volume":"42","author":"Ali","year":"2020","journal-title":"Ren Fail"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.tp.0000219817.18049.36","article-title":"Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients","volume":"81","author":"Opelz","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0019","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.trim.2015.04.003","article-title":"Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: an update","volume":"32","author":"Hertig","year":"2015","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0021","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.transproceed.2010.02.088","article-title":"Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis","volume":"42","author":"Liu","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0022","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2019.10.045","article-title":"Immune activation, immune senescence and levels of Epstein Barr virus in kidney transplant patients: impact of mTOR inhibitors","volume":"469","author":"Petrara","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0023","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/ajt.15216","article-title":"Dual blockade of the PI 3K\/Akt\/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival","volume":"19","author":"Sang","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.TP.0000085602.22498.CF","article-title":"Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?","volume":"76","author":"Birkeland","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0026","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0027","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0028","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder: EBV status in PTLD","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0029","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.1998.16.6.2052","article-title":"Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?","volume":"16","author":"Leblond","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0030","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0031","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1600-6143.2004.00521.x","article-title":"Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature","volume":"4","author":"Rajakariar","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0032","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","article-title":"Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma","volume":"101","author":"Toro","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0033","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/ejh.12439","article-title":"Gamma-delta t-cell lymphomas","volume":"94","author":"Foppoli","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0034","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0035","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","article-title":"Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment","volume":"20","author":"Falchook","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0036","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1046\/j.1365-2141.2002.03537_3.x","article-title":"Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin","volume":"117","author":"Iannitto","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","article-title":"Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience","volume":"13","author":"Voss","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0038","article-title":"Cutaneous gamma\/delta T-cell lymphoma","volume":"7","author":"Koch","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0039","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2340\/00015555-1460","article-title":"Allogeneic haematopoietic stem cell transplantation in a patient with cutaneous \u03b3\/\u03b4-T-cell lymphoma","volume":"93","author":"Terras","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ki.2013.253","article-title":"Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival","volume":"85","author":"Serre","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0041","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0042","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/tri.12375","article-title":"CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality","volume":"27","author":"Rabot","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0043","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients","volume":"71","author":"Tsai","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0044","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.transproceed.2015.03.017","article-title":"Post-transplant lymphoproliferative disorder: a single-center experience","volume":"47","author":"Ferreira","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Choquet","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0046","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/01.tp.0000258647.50947.78","article-title":"Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab","volume":"83","author":"Trappe","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0047","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.10595","article-title":"CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation","volume":"92","author":"Choquet","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0048","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with rituximab or chemotherapy: rituximab or chemotherapy for treatment of PTLD","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.020_bib0049","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521003122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521003122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:39:58Z","timestamp":1758577198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134521003122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0041134521003122"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.04.020","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous Manifestations of Posttransplant Lymphoma in Renal Transplant Recipients: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}